具体参见2025年3月31日报告《IL-4R突围,看好双抗&ADC矩阵——康诺亚2024年报业绩点评》,如需报告全文或数据底稿,请联系团队成员或对口销售。投资要点我们看好司普奇拜领先优势,以及差异化&疗效优势奠定的突围基础。 期待 ADC&双抗平台丰富的肿瘤&自免产品矩阵打造的竞争优势和估值溢价。业绩:司普奇拜实现商业化,差异化&疗效优势奠定突围基础2024年公司整体收入4.28亿元,包括合作收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.